The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.
Suhexiang Pill, a traditional Chinese patent medicine, is widely used in China for acute stroke. However, there is a lack of evidence of its efficacy and safety for acute ischemic stroke in real-world setting. This registry study will recruit 1000 patients who receive Suhexiang Pill treatment after acute ischemic stroke.
Study Type
OBSERVATIONAL
Enrollment
1,000
Suhexiang Pill is an approved traditional Chinese patent medicine.
Dongzhimen Hospital
Beijing, Beijing Municipality, China
NOT_YET_RECRUITINGDongzhimen Hospital
Beijing, Beijing Municipality, China
RECRUITINGProportion of patients independent
Proportion of patients independent is defined as the modified Rankin Scale score of 0, 1, or 2.
Time frame: 90 days
National Institute of Health Stroke Scale
The National Institute of Health Stroke Scale (NIHSS) ranges from 0 to 42, with higher scores indicating more severe neurological deficits.
Time frame: The change from baseline to day 10 or discharge.
Glasgow Coma Scale
The Glasgow Coma Scale (GCS) is used to describe the extent of impaired consciousness in all types of acute medical and trauma patients, ranging from 0 to 15, with lower scores indicating more severe impaired consciousness.
Time frame: The change from baseline to day 10 or discharge.
Patient reported outcome
The patient reported outcome (PRO) scale of stroke consists of four dimensions including the influence on physical, emotional, and social functioning, as well as the overall satisfaction with treatment.
Time frame: At day 10 or discharge.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.